

January 26, 2011
Nagase & Co., Ltd.

Nagase Announces a Business and Capital Alliance with RIKEN Venture Firm TAGCYX

Tokyo, Japan, January 26, 2011—Nagase & Co., Ltd. (Tokyo, Japan; TSE: 8012) today announced that it has entered into a strategic business and alliance with TAGCYX Biotechnologies (Yokohama, Japan) to develop marketing opportunities in nucleic acid-based therapeutics* and molecular diagnostics. TAGCYX is a worldwide leader in unnatural base pair and nucleic acid stabilization technologies.

Through this alliance, Nagase will enhance its activities in biopharmaceuticals** and molecular diagnostics, especially by developing TAGCYX's technology in nucleic acid-based therapeutics.

Nagase and TAGCYX will partner with pharmaceutical companies which develop nucleic acid-based therapeutics using TagCyx technology. Nagase will support such activities through collaborative research and joint product development, including ingredient sourcing and product manufacturing.

Nucleic acid-based therapeutics, as a next generation of novel therapeutics, are expected to fulfill unmet medical needs.

Nagase will pursue new business opportunities, using its manufacturing capabilities and global network, to support the development of nucleic acid-based therapeutics and molecular diagnostics by pharmaceutical and biotech companies.

Life sciences are one of the Nagase Group's key business areas, and the group is engaging a range of pharmaceutical-related businesses. Through this alliance, the Nagase Group also intends to pursue value chain development in the biopharmaceuticals industry.

*Nucleic acid-based therapeutics uses short fragments of nucleic acid as a pharmaceutical agent which regulate the target gene functions.

**Biopharmaceuticals are drugs produced using biotechnologies, including recombinant DNA technology, cell fusion, and mass cell culture. They include protein-based therapeutics, such as hormones and antibodies, cell-based drugs, such as those using skin cell cultures, and nucleic acid drugs, such as DNA, RNA and Antisense oligonucleotides.

TAGCYX Corporate Profile

Company name	TAGCYX Biotechnologies
Representative	Ichiro Hirao, President and Chief Executive Officer
Headquarters	1-6-126 Suehiro-cho, Tsurumi-ku, Yokohama-shi, Kanagawa 230-0045 Japan (Yokohama Bio Industry Center)
Establishment date	March 22, 2007
Main business lines	Based on nucleic acid stabilization technology and the unnatural base-pair system: <ol style="list-style-type: none">1. Diagnostics2. Oligonucleotide therapeutics3. Research reagent business
Paid-in capital	95,860,000 yen
Website	http://tagcyx.com/

Inquiries about this announcement:

Takuji Sekine
Business Development
Fine Chemicals Division
Nagase & Co., Ltd.
Ph: +81 3-3665-3333